Stephen Hoge, Moderna president (Matthew Busch/Bloomberg via Getty Images)

Mod­er­na wants an ac­cel­er­at­ed ap­proval for its can­cer vac­cine — but it's wait­ing on three things

Mod­er­na has tout­ed the pos­si­bil­i­ty of an ac­cel­er­at­ed ap­proval for its Mer­ck-part­nered can­cer vac­cine by 2025. But ac­cord­ing to ex­ec­u­tives, three things need to hap­pen first.

Mer­ck and Mod­er­na made news in De­cem­ber 2022 when they un­veiled Phase II da­ta sug­gest­ing their in­di­vid­u­al­ized neoanti­gen ther­a­py, or INT, re­duced the risk of can­cer re­cur­rence or death in melanoma pa­tients when used with Mer­ck’s Keytru­da. The da­ta rein­vig­o­rat­ed a field that has frus­trat­ed sci­en­tists for years. The ther­a­py is now in two Phase III tri­als in ad­ju­vant melanoma and non-small cell lung can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.